Ligand Pharmaceuticals Incorporated (LGND)
After hours:
| Previous close | 103.15 |
| Open | 103.83 |
| Bid | 100.68 x 100 |
| Ask | 101.57 x 100 |
| Day's range | 99.08 - 104.89 |
| 52-week range | 49.24 - 112.13 |
| Volume | |
| Avg. volume | 125,083 |
| Market cap | 1.848B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | 43.41 |
| EPS (TTM) | 2.33 |
| Earnings date | 06 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 July 2010 |
| 1y target est | 124.00 |
Business WireLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
JUPITER, Fla., September 06, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI.
GuruFocus.comInsider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
The transaction was executed at a price of $105.34 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 49,510 shares of Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Inc is engaged in the development and licensing of biopharmaceutical assets.
Business WireLigand to Present at H.C. Wainwright 26th Annual Global Investment Conference
JUPITER, Fla., August 20, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
